Diana Brainard - Jul 1, 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role: Chief Executive Officer, Director
Signature: /s/ Brett Hagen, as Attorney-in-Fact
Stock symbol: ALVR
Transactions as of: Jul 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/6/2022, 07:30 AM
Previous filing: May 23, 2022
Next filing: Aug 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALVR	Common Stock	Award	$0	+48.1K	+9.74%	$0.00	542K	Jul 1, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALVR	Stock Option (Right to Buy)	Award	$0	+89.4K		$0.00	89.4K	Jul 1, 2022	Common Stock	89.4K	$4.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2	Includes 1,822 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022.
F3	25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.